| 本文已被：浏览 1513次 下载 1536次 |
码上扫一扫！ |
|
|
| 津力达颗粒联合二甲双胍治疗新诊断2型糖尿病患者的临床观察 |
|
赵进东1, 李艳1, 刘诗富2, 曹会波3, 裴国勇4, 哈团结5, 汪晓鸿6, 陆平7, 毕道银8, 牛云飞1, 舒仪琼1, 丁雷1, 倪英群1, 陆瑞敏1, 李家云1, 方朝晖1
|
|
1.安徽中医药大学第一附属医院, 合肥 230031;2.安徽省芜湖市中医院, 芜湖 241000;3.安徽省滁州市中西医结合医院, 滁州 239000;4.安徽省黄山市中医院, 黄山 242700;5.安徽省太和县中医院, 太和 236600;6.安徽省宁国市中医院, 宁国 242300;7.安徽省利辛县中医院, 利辛 236700;8.安徽省长丰县中医院, 长丰 231100
|
|
| 摘要: |
| [目的]观察津力达颗粒联合二甲双胍治疗新诊断2型糖尿病患者的安全性及有效性。[方法]总计156名新诊断2型糖尿病患者参与研究。所有患者在接受二甲双胍常规治疗基础上，被随机分配服用津力达颗粒（治疗组）或安慰剂（对照组）。研究终点为随访第12周受试者糖化血红蛋白（HbA1c）、空腹血糖（FPG）、餐后2 h血糖（2 h PG）。[结果]在12周随访时，治疗组HbA1c为（6.61±0.63）%，安慰剂组HbA1c为（6.91±1.09）%，差异有统计学意义（P<0.05）；治疗组FPG为（7.31±1.12）mmol/L，安慰剂组FPG为（7.63±0.77）mmol/L；治疗组2 h PG为（10.63±1.80）mmol/L，安慰剂组2 h PG为（11.46±2.42）mmol/L，差异均具有统计学意义（P<0.05）。治疗组达标率为83.3%，对照组为67.9%；治疗组中医证候有效率为85.8%，对照组为57.7%，差异有统计学意义（P<0.05）。2组均未发生与研究药物相关的严重不良事件。[结论]研究结果显示，在二甲双胍治疗基础上，联合使用津力达颗粒可使新诊断2型糖尿病患者血糖水平得到更好控制，应用于新诊断2型糖尿病患者安全有效。 |
| 关键词: 新诊断2型糖尿病 从脾论治 津力达颗粒 二甲双胍 |
| DOI：10.11656/j.issn.1673-9043.2017.05.08 |
| 分类号:R587.1 |
| 基金项目:国家中医药管理局中医药重点学科项目（20091221）；国家自然科学基金项目（81573944）；国家自然科学基金项目（81603574）；安徽省自然科学基金项目（1708085QH213）；国家中医临床研究基地业务建设第二批科研专项项目（JDZX2015123）；安徽中医药大学科学研究基金项目（2015qn029）。 |
|
| The clinical observation of Jinlida granule as Add-On metformin treat the newly diagnosed type 2 diabetic patients |
|
ZHAO Jin-dong1, LI Yan1, LIU Shi-fu2, CAO Hui-bo3, PEI Guo-yong4, HA Tuan-jie5, WANG Xiao-hong6, LU Ping7, BI Dao-yin8, NIU Yun-fei1, SHU Yi-qiong1, DING Lei1, NI Ying-qun1, LU Rui-min1, LI Jia-yun1, FANG Zhao-hui1
|
|
1.The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, China;2.Wuhu Hospital of Chinese Medicine, Wuhu 241000, China;3.Chuzhou Hospital of Chinese Medicine and Western medicine, Chuzhou 239000, China;4.Huangshan Hospital of Chinese Medicine, Huangshan 242700, China;5.Taihe Hospital of Chinese Medicine, Taihe 236600, China;6.Ningguo Hospital of Chinese Medicine, Ningguo 242300, China;7.Lixin Hospital of Chinese Medicine, Lixin 236700, China;8.Changfeng Hospital of Chinese Medicine, Changfeng 231100, China
|
| Abstract: |
| [Objective] To observe the safety and efficacy of Jinlida granule combined with metformin in the treatment of newly diagnosed type 2 diabetes mellitus.[Methods] A total of 156 newly diagnosed type 2 diabetic patients were enrolled in the study. All of the patients on the basis of metformin to conventional treatment, were randomly assigned to take Jinlida granule(treatment group) or placebo (control group). The end of the study was followed by the 12th week of subject Glycated HemoglobinA1c(HbA1c), Fasting plasma glucose(FPG), 2 h postprandial glucose(2 h PG).[Results] At 12 weeks of follow-up, the treatment group HbA1c was (6.61±0.63)%, the placebo group HbA1c was (6.91±1.09)%. The difference was statistically significant(P<0.05). The FPG of the treatment group was (7.31±1.12) mmol/L. The placebo group FPG was (7.63±0.77). The 2 h PG of the treatment group was (10.63±1.80) mmol/L. The placebo group 2 h PG was (11.46±2.42) mmol/L. The difference was statistically significant(P<0.05). The treatment group success rate was 83.3%, the control group is 67.9%. The effective rate of Chinese Medicine(CM) syndromes was 85.8% in the treatment group and 57.7% in the control group, the difference was statistically significant (P<0.05). Two groups of treatment group were not serious adverse events related to study drug.[Conclusion] The results showed that on the basis of metformin treatment, combination of Jinlida granule can make the patients with newly diagnosed type 2 diabetes better control of blood sugar level. Applied in newly diagnosed type 2 diabetes is safe and effective. |
| Key words: newly diagnosed type 2 diabetes treatment determination from spleen Jinlida granule metformin |
